Malondialdehyde Formation in Rat Platelet-Rich Plasma

Summary

The type of inhibition and the relative potency of aspirin and indomethacin on rat platelet malondialdehyde (MDA) formation were investigated in an in vitro system. Both drugs inhibited the production of MDA after platelet stimulation with either thrombin (10 or 25 NIH u/ml) or sodium arachidonate (0.5–2.25 mM).

Inhibition by both drugs was concentration-dependent, was partially removed when platelet-rich plasma was diluted with platelet-poor plasma, was much stronger when either drug was preincubated with platelets for 10 minutes than for 1 minute and was apparently competitive when analysed by Dixon plots (1/V versus inhibitor concentrations).

It is suggested that both aspirin and indomethacin may inhibit in vitro cyclo-oxygenase activity in citrated platelet-rich plasma by a similar, if not identical, partially reversible mechanism, not involving – in a first step – covalent binding of either drug to enzyme.

A scheme of the interaction of both drugs with cyclo-oxygenase is presented which also takes into account the irreversible acetylation of the enzyme occurring after longer incubation times with aspirin.

Key words

Blood platelets - Arachidonic acid metabolism - Malondialdehyde - Thrombin - Aspirin - Indomethacin - Kinetic analysis

• References

• 1 Smith JB, Silver MJ. Prostaglandin synthesis by platelets and its biological significance. In: Platelets in Biology and Pathology . Gordon JL. ed) Amsterdam, North-Holland: 1976. pp 331-352
• 2 Rajtar G, Livio M, Merino J, De Gaetano G. Malondialdehyde formation in rat platelet-rich plasma. I. A kinetic approach. Thromb Haemostas 1980; 44: 49-51
• 3 Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108
• 4 Dixon M. The determination of enzyme-inhibitor constants. Biochem J 1953; 55: 170-171
• 5 Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33-67
• 6 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632
• 7 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076
• 8 Riegelman S. The kinetic disposition of aspirin in human. In: Aspirin, Platelets and Stroke. Background for a Clinical Trial. Fields WS, Hass WK. eds) St Louis, Mo Warren, H Green Inc: 1971. pp 105-114
• 9 Rome LH, Lands WE M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975; 72: 4863-4865
• 10 Rome LH, Lands WE M. Inhibition of prostaglandin synthesis. Fed Proc 1975; 34: 790
• 11 Purich DL, Fromm HJ. Limitations in the use of Dixon plots to evaluate enzyme inhibition. Biochim Biophys Acta 1972; 268: 1-3
• 12 Vargaftig BB. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 1978; 50: 231-241
• 13 Merino J, Livio M, Rajtar G, De Gaetano G. Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem Pharmacol 1980; 29: 1093-1096
• 14 Stanford N, Roth GJ, Shen TY, Majerus PW. Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins 1977; 13: 669-675
• 15 O'Brien JR. Effect of anti-inflammatory agents on platelets. Lancet 1968; 1: 894-895
• 16 Kocsis JJ, Hernandovich J, Silver MJ, Smith JB, Ingerman C. Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins 1973; 3: 141-144
• 17 De Gaetano G, Donati MB, Vermylen J. Some effects of indomethacin on platelet function, blood coagulation and fibrinolysis. Int J Clin Pharmacol Ther Toxicol 1971; 5: 196-199